Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardiacAssist Inc.

This article was originally published in Start Up

Executive Summary

CardiacAssist has gotten off the beaten path of ventricular assist device companies (VAD) vying for a piece of the congestive heart failure market. It is positioning its own implantable VAD as a percutaneous device that can serve the needs of cardiogenic shock patients, by bridging them to therapeutic interventions.

You may also be interested in...



CardiacAssist Builds a Bridge to the Next Bridge

CardiacAssist operates in the market for acute heart failure, with TandemHeart a pump designed to reverse multi-organ failure, to help the heart recover, or at the very least, keep patients alive so they can move on to the next therapeutic option. A lot has happened since Start-Up spoke with CardiacAssist back in 2002. The company's TandemHeart gained 510(k) clearance in 2003, and by January 2009, more than 1,500 TandemHeart procedures had been performed. The pace of adoption is accelerating. Now, with sales of $10 million, and a steady 40% growth rate, the company is no longer dependent upon venture capital.

The Failing Heart

Looking for larger patient populations, the newer CHF device companies position their products as early intervention tools that can perhaps delay or halt the progression of the disease.

Minute Insight: FundamentalVR Raises $20M In Series B, Further Develop HapticVR For Surgical Training

Fundamental VR, which developed a virtual surgical platform that uses advanced technologies such as haptic (touch) feedback, announced on 11 August it raised $20m in a series B round led by EQT Life Sciences and prior investors Downing Ventures.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel